Luca Massimino
Overview
Explore the profile of Luca Massimino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cannarozzi A, Biscaglia G, Parente P, Latiano T, Gentile A, Ciardiello D, et al.
Crit Rev Oncol Hematol
. 2025 Mar;
:104694.
PMID: 40064251
Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Despite advances in screening and treatment, CRC is heterogeneous and the response to therapy varies significantly,...
2.
Barchi A, DellAnna G, Massimino L, Mandarino F, Vespa E, Viale E, et al.
Front Oncol
. 2025 Feb;
14:1458138.
PMID: 39950103
Barrett's esophagus (BE) represents a pre-cancerous condition that is characterized by the metaplastic conversion of the squamous esophageal epithelium to a columnar intestinal-like phenotype. BE is the consequence of chronic...
3.
Barchi A, Massimino L, Mandarino F, Yacoub M, Albarello L, Savarino E, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39675404
Background & Aims: Our aim was to evaluate the outcomes of maintenance treatments for eosinophilic esophagitis (EoE) among observational studies (OSs) and randomized controlled trials (RCTs). Materials And Methods: Studies...
4.
Villa M, Sharma G, Malighetti F, Mauri M, Arosio G, Cordani N, et al.
Br J Cancer
. 2024 Oct;
131(11):1781-1795.
PMID: 39478125
Background: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene....
5.
Cannarozzi A, Massimino L, Latiano A, Parigi T, Giuliani F, Bossa F, et al.
Comput Struct Biotechnol J
. 2024 Sep;
23:3407-3417.
PMID: 39345902
Inflammatory bowel diseases (IBD) are classified into two entities, namely Crohn's disease (CD) and ulcerative colitis (UC), which differ in disease trajectories, genetics, epidemiological, clinical, endoscopic, and histopathological aspects. As...
6.
Barchi A, Mandarino F, Yacoub M, Albarello L, Massimino L, Savarino E, et al.
Biomolecules
. 2024 Sep;
14(9).
PMID: 39334846
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus. EoE shares a common pathogenetic mechanism with other chronic disorders pertaining to the type 2 inflammatory spectrum, such as...
7.
Parigi T, Massimino L, Carini A, Gabbiadini R, Bertoli P, Allocca M, et al.
J Crohns Colitis
. 2024 Sep;
PMID: 39269323
Background And Aim: Criteria for "difficult-to-treat" Inflammatory Bowel Disease (IBD) (DTT-IBD) have recently been proposed to standardize terminology. We aimed to evaluate the prevalence, characteristics, management, and outcomes of DTT-IBD....
8.
Cannarozzi A, Latiano A, Massimino L, Bossa F, Giuliani F, Riva M, et al.
United European Gastroenterol J
. 2024 Aug;
12(10):1461-1480.
PMID: 39215755
Various extrinsic and intrinsic factors such as drug exposures, antibiotic treatments, smoking, lifestyle, genetics, immune responses, and the gut microbiome characterize ulcerative colitis and Crohn's disease, collectively called inflammatory bowel...
9.
Bernardi F, Ungaro F, DAmico F, Zilli A, Parigi T, Massimino L, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125870
Immune-mediated gastrointestinal (GI) diseases, including achalasia, celiac disease, and inflammatory bowel diseases, pose significant challenges in diagnosis and management due to their complex etiology and diverse clinical manifestations. While genetic...
10.
DAmico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, et al.
Eur J Clin Invest
. 2024 Jul;
54(11):e14283.
PMID: 38979834
Background And Aims: Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of...